cyproheptadine has been researched along with Ovarian Neoplasms in 1 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian cancer (EOC) and the potential use of its antagonist, rupatadine, as an experimental treatment." | 4.02 | The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. ( Beyer, S; Burges, A; Chelariu-Raicu, A; Czogalla, B; Deuster, E; Hester, A; Hysenaj, I; Jeschke, U; Kahaly, M; Kolben, T; Kraus, F; Mahner, S; Mayr, D; Schmoeckel, E; Trillsch, F, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deuster, E | 1 |
| Hysenaj, I | 1 |
| Kahaly, M | 1 |
| Schmoeckel, E | 1 |
| Mayr, D | 1 |
| Beyer, S | 1 |
| Kolben, T | 1 |
| Hester, A | 1 |
| Kraus, F | 1 |
| Chelariu-Raicu, A | 1 |
| Burges, A | 1 |
| Mahner, S | 1 |
| Jeschke, U | 1 |
| Trillsch, F | 1 |
| Czogalla, B | 1 |
1 other study available for cyproheptadine and Ovarian Neoplasms
| Article | Year |
|---|---|
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyproheptadine; ErbB Rece | 2021 |